Market revenue in 2023 | USD 255.7 million |
Market revenue in 2030 | USD 318.7 million |
Growth rate | 3.2% (CAGR from 2023 to 2030) |
Largest segment | Reagents and consumables |
Fastest growing segment | Reagents and Consumables |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Instruments, Reagents and Consumables |
Key market players worldwide | BioMerieux SA, BD, Danaher Corp, Seegene, T2 Biosystems Inc, Roche, Siemens Healthineers AG ADR, Luminex, Bruker Corp, Accelerate Diagnostics Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to bloodstream infection testing market will help companies and investors design strategic landscapes.
Reagents and consumables was the largest segment with a revenue share of 88.27% in 2023. Horizon Databook has segmented the U.S. bloodstream infection testing market based on instruments, reagents and consumables covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. bloodstream infection testing market, including forecasts for subscribers. This country databook contains high-level insights into U.S. bloodstream infection testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account